Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Aurora St. Luke's Medical Center Gynecologic Oncology
mi
from
Milwaukee, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Aurora St. Luke's Medical Center Gynecologic Oncology
mi
from
Milwaukee, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Aspirus Regional Cancer Center
mi
from
Wausau, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Stanford University School of Medicine
mi
from
Stanford, CA
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
University of Massachusetts Memorial Healthcare
mi
from
Worcester, MA
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
University of Massachusetts Memorial Healthcare
mi
from
Worcester, MA
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Henry Ford Health System
mi
from
Detroit, MI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Ohio State University Medical Center
mi
from
Columbus, OH
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Methodist Hospital
mi
from
Houston, TX
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Green Bay Oncology at St. Vincent's Hospital
mi
from
Green Bay, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Green Bay Oncology at St. Vincent's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
St. Vincent Hospital
mi
from
Green Bay, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Green Bay Oncology at St. Mary's Hospital
mi
from
Green Bay, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Green Bay Oncology at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Holy Family Memorial Medical Center
mi
from
Manitowoc, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Holy Family Memorial Medical Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Bay Area Medical Center
mi
from
Marinette, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  7/20/2016
Marshfield Clinic
mi
from
Marshfield, WI
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 7/20/2016
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
University of CA at Irvine Chao Cancer Center
mi
from
Orange, CA
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
University of CA at Irvine Chao Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  7/26/2016
Clinical Research Facility
mi
from
New York, NY
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 7/26/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  7/26/2016
Investigational Site Number 3413
mi
from
Madrid,
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 7/26/2016
Investigational Site Number 3413
mi
from
Madrid,
Click here to add this to my saved trials
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New Haven, CT
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Research Site
mi
from
Barcelona,
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Jacksonville, FL
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Rochester, MN
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
mi
from
Amsterdam,
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
mi
from
Amsterdam,
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salinas, CA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salinas, CA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Whittier, CA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Englewood, CO
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Farmington, CT
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New Britain, CT
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hinsdale, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Joliet, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Skokie, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials